Grail to cut jobs, planned hires for 2024 by about 30%-March 2024-www.financetom.com

Grail to cut jobs, planned hires for 2024 by about 30%

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

Grail to cut jobs, planned hires for 2024 by about 30%

Aug 13, 2024 1:28 PM

Aug 13 (Reuters) - Cancer test maker Grail said

on Tuesday it would reduce existing headcount and planned hires

for 2024 by about 30%, as part of its restructuring program.

Previous page： Police investigate possible arson as Rome fire destroys 17 Teslas Next page： --NewtekOne Keeps Quarterly Dividend at $0.19 Per Share, Payable April 30 to Holders of Record April 15

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Police investigate possible arson as Rome fire destroys 17 Teslas

Mar 31, 2025

ROME, March 31 (Reuters) - Italian police are investigating possible arson at a Tesla dealership in Rome overnight that destroyed 17 cars, a security source said on Monday. Italy's anti-terrorism police unit Digos is leading the investigation and is looking into the possibility that anarchists set fire to the cars on the eastern outskirts of Rome, the source said. Drone...

--NewtekOne Keeps Quarterly Dividend at $0.19 Per Share, Payable April 30 to Holders of Record April 15

Mar 31, 2025

11:18 AM EDT, 03/31/2025 (MT Newswires) -- Price: 11.93, Change: +0.07, Percent Change: +0.55 ...

AuthID Shares Fall Following $8.15 Million Direct Stock Offering

Mar 31, 2025

11:20 AM EDT, 03/31/2025 (MT Newswires) -- AuthID ( AUID ) shares fell 25% in recent Monday trading after the company announced a registered direct offering of 1.81 million common shares and prefunded warrants, priced at $4.50 apiece, to raise $8.15 million. The proceeds will be for general corporate purposes and working capital, the company said Monday in a statement....

CERo Gets FDA Clearance for CER-1236 Trial in Solid Tumors

Mar 31, 2025

11:20 AM EDT, 03/31/2025 (MT Newswires) -- CERo Therapeutics ( CERO ) said Monday the US Food and Drug Administration has cleared its second investigational new drug application for CER-1236 for a phase 1 trial in advanced solid tumors, specifically non-small cell lung cancer and ovarian cancer. Following the launch of our AML trial, we are now starting a second...